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ole of Lipoprotein(a) in
ardiovascular Disease
urrent and Future Perspectives*
ars Berglund, MD, PHD, FAHA,†‡
rdembileg Anuurad, MD, PHD†
avis and Sacramento, California
he clinical interest in lipoprotein(a) [Lp(a)] is largely
erived from its role as a cardiovascular risk factor. Al-
hough not considered an established risk factor, Lp(a)
evels have been associated with cardiovascular disease in
umerous studies (1–3). Further, there is emerging evidence
f interaction between Lp(a) and other established and
otential cardiovascular risk factors, such as low-density
ipoprotein (LDL) cholesterol, high-density lipoprotein
HDL) cholesterol, and homocysteine (4–6).
See page 124
Lipoprotein(a) has many features in common with LDL.
owever, in contrast to LDL, the distribution of plasma Lp(a)
evels is very skewed, ranging from 0.1 to 300 mg/dl (7).
otably, especially among Caucasians, only a minority of
ndividuals have Lp(a) levels30 mg/dl, which are commonly
ssociated with risk (1,8). This skewed distribution and the fact
hat very few subjects have high levels of Lp(a) represent
hallenges in firmly associating Lp(a) with disease. Another
hallenge has been the standardization of Lp(a) measurements.
lthough LDL is expressed as cholesterol levels, the Lp(a)
evel reflects particle concentrations, including both lipid and
rotein components. The use of mass units in many Lp(a)
ssays requires an assumption of a particular apolipoprotein(a)
apo(a)] mass, that is, ignoring apo(a) size variation. The use of
olar units (e.g., nmol/l) is therefore preferable. Because many
mmunological assays are based on epitopes in the repeating
nits of apo(a), the high degree of heterogeneity of apo(a) and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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alifornia. Dr. Berglund has received consulting fees from Merck, Novartis, and
erck/Schering-Plough; has received lecture fees from Merck, AstraZeneca, and
erck/Schering-Plough; and has equity interest in Pfizer. This work was supported
n part by the University of California, Davis Clinical and Translational Sciencea
enter (RR 024146), and Dr. Anuurad is a recipient of an American Heart
ssociation Postdoctoral Fellowship (0725125Y).he high degree of sequence similarity between apo(a) and
lasminogen represent additional challenges for measurement
f Lp(a). However, assays are available based on unique,
onrepeating apo(a) epitopes. Further, beyond methodological
ssues, in the majority of cases the plasma Lp(a) level consti-
utes a sum of Lp(a) carried in particles representing 2 different
izes of apo(a) molecules, that is, allele-specific apo(a) levels.
or a given apo(a) size, there is considerable variability in
llele-specific apo(a) levels. To date, available commercial
ssays do not take the relative distribution across apo(a) alleles
nto account.
In this issue of the Journal, Danik et al. (9) report results
rom a cohort study addressing the effect of hormone
eplacement therapy (HT) on Lp(a) and cardiovascular risk.
onfirming previous findings suggesting a lowering effect of
strogen on Lp(a), the investigators showed that Lp(a)
alues were lower among women taking HT. They have
urther explored the effect of HT on the relationship of
p(a) with cardiovascular disease (CVD). In women not
aking HT, after appropriate adjustment for confounders,
he hazard ratio of future CVD for the highest Lp(a)
uintile compared with the lowest quintile was 1.77 (p 
.0001 for trend). In contrast, among women taking HT
here were no such significant associations with CVD.
otably, the effect of HT was observed only in women with
igh LDL cholesterol levels, in agreement with previous
tudies suggesting an interaction between Lp(a) and LDL
holesterol (Fig. 1). Further, the association was not linear
nd was limited to the highest Lp(a) quintile. This inter-
sting observation suggests that there may be a threshold
ffect in the role of Lp(a) as a risk factor. Further, the
nteraction observed with LDL cholesterol levels indicates
hat Lp(a) might have more pronounced risk factor prop-
rties in a high-risk environment. The article has a number
f strengths, including the use of an assay insensitive to
po(a) size variation, the inclusion of a relatively large
umber of subjects, and the ability to address whether HT
as an impact on cardiovascular risk associated with Lp(a).
Although an apo(a) size-insensitive assay was used, allele-
pecific levels were not analyzed. Previous studies have
hown an association between plasma Lp(a) levels and
ardiovascular disease or pre-clinical vascular changes in
ubjects who carry at least 1 small apo(a) isoform (10–13).
hese results indicate that cardiovascular risk associated
ith Lp(a) may be pronounced among subjects carrying
mall apo(a) sizes. Availability of isoform-specific or allele-
pecific levels may therefore provide further information in
ssessing risk attributable to Lp(a) (13,14). In the study by
uck et al. (15), estrogen treatment among healthy post-
enopausal women resulted in a decrease of Lp(a) levels,
nd notably a reduction was observed for both small and
arge apo(a) sizes. Further studies may provide insight on
hether the modification of risk in the present study may bettributable to a reduction of risk conveyed by small apo(a).
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July 8, 2008:132–4 Editorial CommentIn assessing appropriate cardiovascular preventive mea-
ures, the issue of whether an intervention to lower Lp(a) is
linically warranted arises. At present, there are no guide-
ines recommending intervention based on high Lp(a) levels
16,17). The current study, as well as recent findings from
ther studies (4–6,18,19), suggest that Lp(a)-lowering
herapy might be beneficial, at least in some subgroups of
atients with high Lp(a) levels. However, at present, details
re lacking on how to define such subgroups with regard to
p(a) levels, apo(a) size, and the presence of other risk
actors. Shlipak et al. (20) reported that a combination of
strogen and progestin seems to have a more favorable effect
n women with high initial Lp(a) levels, and this effect
ccurs among women with known coronary artery disease.
owever, except for this subgroup of women in the HERS
Heart and Estrogen/Progestin Replacement Study) (20),
o conclusive effect of Lp(a) lowering on coronary artery
isease has previously been reported. The present findings
re encouraging because they provide evidence that high
p(a) levels in a high-risk setting might be appropriate to
onsider an intensified intervention. However, further stud-
es are needed to firmly assess any possible therapeutic
enefits of a reduction of Lp(a) levels.
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ent of Medicine, University of California, Davis Medical Center,
linical and Translational Science Center, 2921 Stockton Boulevard,
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Figure 1 Potential Mechanism for the Impact of Hormone Repl
Treatment on Risk Factor Properties of Lp(a) in a Hig
The concept of cardiovascular risk mediated by high levels of lipoprotein(a) [Lp(a)]
els. In the absence of hormone replacement treatment (HT), high Lp(a) levels are
the risk is attenuated in the presence of HT. Apo  apolipoprotein.cdmc.ucdavis.edu.EFERENCES
1. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904–10.
2. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipopro-
tein(a) and coronary heart disease in men aged 55 years and younger.
A prospective study. JAMA 1996;276:544–8.
3. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and
coronary heart disease risk: a nested case-control study of the Helsinki
Heart Study participants. Atherosclerosis 1991;89:59–67.
4. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ,
Albers JJ. Effects of lowering elevated LDL cholesterol on the
cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771–4.
5. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW,
Sprecher DL. Homocysteine and lipoprotein(a) interact to increase
CAD risk in young men and women. Arterioscler Thromb Vasc Biol
2000;20:493–9.
6. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a)
further increases the risk of coronary events in men with high global
cardiovascular risk. J Am Coll Cardiol 2001;37:434–9.
7. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz
C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-
lipoprotein concentrations in plasma. J Clin Invest 1987;80:458–65.
8. Marcovina SM, Albers JJ, Jacobs DR Jr., et al. Lipoprotein[a]
concentrations and apolipoprotein[a] phenotypes in Caucasians and
African Americans. The CARDIA study. Arterioscler Thromb 1993;
13:1037–45.
9. Danik JS, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone
replacement therapy, and risk of future cardiovascular events. J Am
Coll Cardiol 2008;52:124–31.
0. Linden T, Taddei-Peters W, Wilhelmsen L, et al. Serum lipids,
lipoprotein(a) and apo(a) isoforms in patients with established coro-
nary artery disease and their relation to disease and prognosis after
coronary by-pass surgery. Atherosclerosis 1998;137:175–86.
1. Ruiz J, Thillet J, Huby T, et al. Association of elevated lipoprotein(a)
levels and coronary heart disease in NIDDM patients. Relationship
with apolipoprotein(a) phenotypes. Diabetologia 1994;37:585–91.
2. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a)
and apolipoprotein(a) phenotype in atherogenesis: prospective results
ent
k Environment
igh-risk environment, such as high low-density lipoprotein [LDL] cholesterol lev-
ated with increased risk in subjects with high LDL cholesterol levels, whereasacem
h-Ris
in a h
associfrom the Bruneck study. Circulation 1999;100:1154–60.
11
1
1
1
1
1
2
K
134 Berglund and Anuurad JACC Vol. 52, No. 2, 2008
Editorial Comment July 8, 2008:132–43. Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and
small apolipoprotein(a) sizes are associated with endothelial dysfunction in
a multiethnic cohort. J Am Coll Cardiol 2004;43:1828–33.
4. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a
small apo(a) isoform are associated with coronary artery disease in
African American and white men. Arterioscler Thromb Vasc Biol
2000;20:2619–24.
5. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipopro-
tein(a) levels: effects of estrogen replacement therapy on lipoprotein(a)
and acute phase reactants in postmenopausal women. Arterioscler
Thromb Vasc Biol 1997;17:1822–9.
6. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the
National Heart, Lung, and Blood Institute Workshop on Lipopro-
tein(a) and Cardiovascular Disease: recent advances and future direc-
tions. Clin Chem 2003;49:1785–96.
7. Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, hand Treatment of High Blood Cholesterol in Adults (Adult Treat-
ment Panel III). JAMA 2001;285:2486–97.
8. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a),
measured with an assay independent of apolipoprotein(a) isoform size,
and risk of future cardiovascular events among initially healthy women.
JAMA 2006;296:1363–70.
9. Cantin B, Despres JP, Lamarche B, et al. Association of fibrinogen
and lipoprotein(a) as a coronary heart disease risk factor in men (The
Quebec Cardiovascular Study). Am J Cardiol 2002;89:662–6.
0. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin,
lipoprotein(a), and the risk of recurrent coronary heart disease events
after menopause. JAMA 2000;283:1845–52.
ey Words: Lp(a) y allele-specific apo(a) levels y risk factors y
ormone replacement therapy y cardiovascular disease.
